Stock Market

On the front-facing side of things, you might not find a better no-brainer (albeit highly speculative) narrative than Zomedica (NYSEAMERICAN:ZOM), the veterinary care specialist focusing on diagnostics platforms. Previously driven by intense meme pressure, ZOM stock found itself providing blistering returns before it all went sour. Source: Postmodern Studio / Shutterstock.com Unlike other meme trades
0 Comments
It’s been a little more than three weeks since Zomedica (NYSEAMERICAN:ZOM) reported its Q2 results. Despite reasonably healthy sales, ZOM stock gained just 14% from Aug. 11 through the end of the month.  Source: Postmodern Studio / Shutterstock.com Another InvestorPlace columnist, Ian Bezek, recently argued that Zomedica needs to raise its revenues considerably before investors
0 Comments
Support.com (NASDAQ:SPRT) holds its special meeting on Sept. 10 to vote on its merger with Greenridge Generation Holdings. The merger’s acceptance requires that more than 50% of owners of SPRT stock vote to approve the deal. Source: Shutterstock.com The two parties announced their merger on March 22. The day before the merger announcement, SPRT closed
0 Comments
Have you seen gene editing and sequencing stocks recently? Source: Connect world / Shutterstock.com Illumina (NASDAQ:ILMN) is up 20% over the past three months. Beam Therapeutics (NASDAQ:BEAM) is up 45%. Editas Medicine (NASDAQ:EDIT) is up 90%. Intellia Therapeutics (NASDAQ:NTLA) is up 150%. Folks, the Genomic Revolution is here. And while everyone can see those big
0 Comments
Although special purpose acquisition companies, or SPACs, gained notoriety over the trailing year-and-a-half period, they do offer a clear advantage to retail investors. Without these blank-check firms, regular folks may not have a chance to buy names like Skillz (NYSE:SKLZ) stock. Source: NYCStock / Shutterstock.com That’s because traditional market debuts are comparatively onerous, perhaps enough
0 Comments
Before Palantir Technologies (NASDAQ:PLTR) issued second quarter earnings early this month, I recommended the stock. Source: rblfmr / Shutterstock.com After analyzing the prospects for its data analysis software, I suggested that if you were looking for the next big thing, “this may be worth nibbling on.” Since then, shares are up 16% as the second
0 Comments